TrialPath

Find a study

Studies of GLP-1, incretin, and related peptide medications for weight and metabolic health.

Match me to a study

3 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Migraine / chronic headache

    Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine

    Studying real-world results of migraine preventive medicines targeting CGRP

    💵 May compensate

    📍 University of Miami, Miller School of Medicine · Miami, FL · Get directions →

    The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.

    ✓ Study care freeAges 18+Learn more →
  • Migraine / chronic headache

    Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

    Testing whether a migraine attack medicine works and is tolerated in people using preventive CGRP

    📍 Mayo Clinic in Arizona · Phoenix, AZ · Get directions →

    Zavegepant (Zavzpret) is approved for the acute treatment of migraine with or without aura in the US. The purpose of this study is to investigate the effectiveness and tolerability of zavegepant for the acute treatment of migraine attacks amongst participants who are using calcitonin gene-related peptide (CGRP) migraine preventive treatments.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Dementia / Alzheimer's

    Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

    Testing a treatment with IL-2 and semaglutide in people with Alzheimer's

    📍 Houston Methodist Research Institute · Houston, TX · Get directions →

    Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited.

    ✓ Study care freePhase 1Ages 50–86Learn more →